Research progress of tumor treating fields in the treatment of glioblastoma

doi:10.3877/cma.j.issn.2095-123X.2020.04.008

Abstract

Abstract:

Tumor therapeutic electric field (TTF) is a kind of low-intensity medium frequency alternating electric field, which has the characteristics of interfering with the mitotic process of cells. It has been proved in vitro that TTF can destroy rapidly dividing tumor cells. At present, the relevant clinical treatment equipment has been approved for the treatment of recurrent glioblastoma (GBM) or newly diagnosed GBM. With the deepening of research and the accumulation of clinical practice, a number of clinical randomized controlled trials have confirmed that TTF can significantly improve the postoperative survival time of GBM patients, and the adverse reactions are mild. Therefore, TTF treatment has been written into the clinical practice guidelines by the National Health Commission Medical Administration of China and the National Comprehensive Cancer Network, and has become the fourth recognized effective treatment for glioma after surgery, chemotherapy and radiotherapy.

Key words: Glioblastoma, Tumor treating fields, Mitosis

Yiqiang Cao, Yonggang Wang, Jiang Long. Research progress of tumor treating fields in the treatment of glioblastoma[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2020, 10(04): 234-238.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2020.04.008

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2020/V10/I04/234

References 38

[26]	Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A^TM system for glioblastoma: the patient registry dataset (PRiDe)[J]. Semin Oncol, 2014, 41 Suppl 6: S4-S13.
[27]	Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial[J]. JAMA, 2017, 318(23): 2306-2316.
[28]	Giladi M, Munster M, Schneiderman RS, et al. Tumor treating fields (TTfields) delay DNA damage repair following radiation treatment of glioma cells[J]. Radiat Oncol, 2017, 12(1): 206.
[29]	Guberina N, Pottgen C, Kebir S, et al. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial[J]. Radiat Oncol, 2020, 15(1): 83.
[30]	Lazaridis L, Schafer N, Teuber-Hanselmann S, et al. Tumour treating fields (TTfields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma[J]. J Cancer Res Clin Oncol, 2020, 146(3): 787-792.
[31]	Stewart G, Eugene H, Lai JS, et al. Pdct-07. Feasibility trial of ttfields (tumor treating fields) for children with recurrent or progressive supratentorial high-grade glioma (HGG) and ependymoma: a pediatric brain tumor consortium study: PBTC-048[J]. Neuro Oncol, 2018, 20(Suppl 6): vi201-vi202
[32]	Tran D, Warren S, Friedman W, et al. Path-27. Identifying the genetic signature of response in a phase II study of tumor treating fields in recurrent glioblastoma[J]. Neuro Oncol, 2018, 20(Suppl 6): vi164.
[33]	Bhr O, Tabatabai G, Fietkau R, et al. P14.63 The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER: TTFields in Germany in routine clinical care)[J]. Neuro Oncol, 2019, 21(Suppl 3): iii82.
[34]	Wick W. TTFelds: where does all the skepticism come from?[J]. Neuro Oncol, 2016, 18(3): 303-305.
[35]	Cloughesy TF, Lassman AB. NovoTTF: where to go from here?[J]. Neuro Oncol, 2017, 19(5): 605-608.
[36]	Burri SH, Gondi V, Brown PD, et al. The evolving role of tumor treating fields in managing glioblastoma: guide for oncologists[J]. Am J Clin Oncol, 2018, 41(2): 191-196.
[37]	Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma[J]. Neuro Oncol, 2016, 18(8): 1129-1136.
[38]	Toms SA, Kim CY, Nicholas G, et al. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial[J]. J Neurooncol, 2019, 141(2): 467-473.
[1]	Brat DJ, Prayson RA, Ryken TC, et al. Diagnosis of malignant glioma: role of neuropathology[J]. J Neurooncol, 2008, 89(3): 287-311.
[2]	Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors[J]. Neurol Clin, 2018, 36(3): 395-419.
[3]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[4]	Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?[J]. Neuro Oncol, 2013, 15(1): 4-27.
[5]	Mun EJ, Babiker HM, Weinberg U, et al. Tumor-treating fields: a fourth modality in cancer treatment[J]. Clin Cancer Res, 2018, 24(2): 266-275.
[6]	Chaudhry A, Benson L, Varshaver M, et al. NovoTTF^TM-100A system (tumor treating fields) transducer array layout planning for glioblastoma: a NovoTAL^TM system user study[J]. World J Surg Oncol, 2015, 13: 316.
[7]	Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality[J]. Eur J Cancer, 2012, 48(14): 2192-2202.
[8]	Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(11): 1537-1570.
[9]	国家卫生健康委员会医政医管局.脑胶质瘤诊疗规范(2018年版)[J].中华神经外科杂志, 2019, 35(3): 217-239.
[10]	Kirson ED, Dbaly V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors[J]. Proc Natl Acad Sci USA, 2007, 104(24): 10152-10157.
[11]	Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors[J]. Onkologie, 2008, 31(7): 362-365.
[12]	Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields[J]. Cancer Res, 2004, 64(9): 3288-3295.
[13]	Gutin PH, Wong ET. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality[J]. Am Soc Clin Oncol Educ Book, 2012: 126-131.
[14]	Gera N, Yang A, Holtzman TS, et al. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit[J]. PLoS One, 2015, 10(5): e0125269.
[15]	Wenger C, Salvador R, Basser PJ, et al. The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study[J]. Phys Med Biol, 2015, 60(18): 7339-7357.
[16]	Kim CY, Paek SH, Nam DH, et al. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial[J]. J Neurooncol, 2020, 146(3): 399-406.
[17]	Karanam NK, Srinivasan K, Ding L, et al. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines[J]. Cell Death Dis, 2017, 8(3): e2711.
[18]	Karanam NK, Ding L, Aroumougame A, et al. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy[J]. Transl Res, 2020, 217: 33-46.
[19]	Shteingauz A, Porat Y, Voloshin T, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTfields)[J]. Cell Death Dis, 2018, 9(11): 1074.
[20]	Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTfields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy[J]. Cancer Immunol Immunother, 2020, 69(7): 1191-1204.
[21]	Kim EH, Song HS, Yoo SH, et al. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis[J]. Oncotarget, 2016, 7(40): 65125-65136.
[22]	Chang E, Patel CB, Pohling C, et al. Tumor treating fields increases membrane permeability in glioblastoma cells[J]. Cell Death Discov, 2018, 4: 113.
[23]	Winkler F, Osswald M, Wick W. Anti-angiogenics: their role in the treatment of glioblastoma[J]. Oncol Res Treat, 2018, 41(4): 181-186.
[24]	Kochar AS, Madhavan M, Manjila S, et al. Contemporary updates on clinical trials of antiangiogenic agents in the treatment of glioblastoma multiforme[J]. Asian J Neurosurg, 2018, 13(3): 546-554.
[25]	Akers KG, Martinez-Canabal A, Restivo L, et al. Hippocampal neurogenesis regulates forgetting during adulthood and infancy[J]. Science, 2014, 344(6184): 598-602.

Please choose a citation manager

Content to export